{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T06:11:14Z","timestamp":1791612674147,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Kyowa Kirin International"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor-induced osteomalacia (TIO) is a rare, acquired condition of phosphate wasting due to phosphaturic mesenchymal tumors. Because the incidence and prevalence of TIO is unknown, we conducted an observational cohort study using national Danish health registers for the period 2008 to 2018 to obtain such information. The study also aimed to describe the demographics of the TIO population and the prognosis. The operational definition was based on hypophosphatemia or adult osteomalacia diagnoses, combined with prescriptions used in the initial management and procedures consistent with advanced imaging used for locating tumors. The incidence of TIO in Denmark was found to be below 0.13 per 100,000 person years for the total population of the country and 0.10 per 100,000 in adult-onset disease. The prevalence of TIO was estimated to be no more than 0.70 per 100,000 persons for the total population and 0.43 per 100,000 in adults. In 2018, there were a maximum of nine new cases of TIO in Danish adults. Mortality was low but few patients fulfilled the protocol cure criterion during the observation period. TIO has no ICD-10 code and limitations to the study include lack of information on serum biochemistry and on the use of phosphate supplements. Strengths include the use of long-term longitudinal, national hospital and prescription data from a country with universal healthcare. Given the very small patient population with TIO and the known delay to diagnosis and cure, management of patients with suspected TIO should be centralized.<\/jats:p>","DOI":"10.1007\/s00223-021-00843-2","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T08:02:27Z","timestamp":1617609747000},"page":"147-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Epidemiology of Tumor-Induced Osteomalacia in Denmark"],"prefix":"10.1007","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2730-6080","authenticated-orcid":false,"given":"Bo","family":"Abrahamsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-9245","authenticated-orcid":false,"given":"Christopher D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6525-0439","authenticated-orcid":false,"given":"Salvatore","family":"Minisola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"key":"843_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.44","volume":"3","author":"S Minisola","year":"2017","unstructured":"Minisola S, Peacock M, Fukumoto S et al (2017) Tumour-induced osteomalacia. Nat Rev Dis Prim 3:1\u201315. https:\/\/doi.org\/10.1038\/nrdp.2017.44","journal-title":"Nat Rev Dis Prim"},{"key":"843_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.clinimag.2019.04.007","volume":"56","author":"SJ Rayamajhi","year":"2019","unstructured":"Rayamajhi SJ, Yeh R, Wong T et al (2019) Tumor-induced osteomalacia\u2014current imaging modalities and a systematic approach for tumor localization. Clin Imaging 56:114\u2013123. https:\/\/doi.org\/10.1016\/j.clinimag.2019.04.007","journal-title":"Clin Imaging"},{"key":"843_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-020-00691-6","author":"P Florenzano","year":"2020","unstructured":"Florenzano P, Hartley IR, Jimenez M, Roszko K, Gafni RI, Collins MT (2020) Tumor-induced osteomalacia. Calcif Tissue Int. https:\/\/doi.org\/10.1007\/s00223-020-00691-6","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"843_CR4","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1210\/er.2017-00220","volume":"39","author":"Y Kinoshita","year":"2018","unstructured":"Kinoshita Y, Fukumoto S (2018) X-linked hypophosphatemia and FGF23-related hypophosphatemic diseases: prospect for new treatment. Endocr Rev 39(3):274\u2013291. https:\/\/doi.org\/10.1210\/er.2017-00220","journal-title":"Endocr Rev"},{"issue":"7","key":"843_CR5","doi-asserted-by":"publisher","first-page":"e10178","DOI":"10.1002\/jbm4.10178","volume":"3","author":"SK Mishra","year":"2019","unstructured":"Mishra SK, Kuchay MS, Sen IB, Garg A, Baijal SS, Mithal A (2019) Successful management of tumor-induced osteomalacia with radiofrequency ablation: a case series. JBMR Plus 3(7):e10178. https:\/\/doi.org\/10.1002\/jbm4.10178","journal-title":"JBMR Plus"},{"issue":"7","key":"843_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","volume":"64","author":"J Feng","year":"2017","unstructured":"Feng J, Jiang Y, Wang O et al (2017) The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases. Endocr J 64(7):675\u2013683. https:\/\/doi.org\/10.1507\/endocrj.EJ16-0587","journal-title":"Endocr J"},{"issue":"9","key":"843_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K et al (2015) Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J 62(9):811\u2013816. https:\/\/doi.org\/10.1507\/endocrj.EJ15-0275","journal-title":"Endocr J"},{"issue":"7","key":"843_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-019-0152-5","volume":"15","author":"D Haffner","year":"2019","unstructured":"Haffner D, Emma F, Eastwood DM et al (2019) Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 15(7):435\u2013455. https:\/\/doi.org\/10.1038\/s41581-019-0152-5","journal-title":"Nat Rev Nephrol"},{"key":"843_CR9","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz203","author":"S Hawley","year":"2020","unstructured":"Hawley S, Shaw NJ, Delmestri A et al (2020) Prevalence and mortality of individuals with X-linked hypophosphatemia: a United Kingdom real-world data analysis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz203","journal-title":"J Clin Endocrinol Metab"},{"key":"843_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG et al (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18:805\u2013835","journal-title":"Epidemiology"},{"key":"843_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/CLEP.S179083","volume":"11","author":"M Schmidt","year":"2019","unstructured":"Schmidt M, Schmidt SAJ, Adelborg K et al (2019) The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 11:563\u2013591. https:\/\/doi.org\/10.2147\/CLEP.S179083","journal-title":"Clin Epidemiol"},{"key":"843_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/CLEP.S37587","volume":"4","author":"SA Johannesdottir","year":"2012","unstructured":"Johannesdottir SA, Horv\u00e1th-Puh\u00f3 E, Ehrenstein V, Schmidt M, Pedersen L, S\u00f8rensen HT (2012) Existing data sources for clinical epidemiology: the Danish National Database of Reimbursed Prescriptions. Clin Epidemiol 4:303\u2013313. https:\/\/doi.org\/10.2147\/CLEP.S37587","journal-title":"Clin Epidemiol"},{"issue":"3","key":"843_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jbmr.3903","volume":"35","author":"X Li","year":"2020","unstructured":"Li X, Jiang Y, Huo L et al (2020) Nonremission and recurrent tumor-induced osteomalacia: a retrospective study. J Bone Miner Res 35(3):469\u2013477. https:\/\/doi.org\/10.1002\/jbmr.3903","journal-title":"J Bone Miner Res"},{"issue":"9308","key":"843_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","volume":"359","author":"SM De Jan Beur","year":"2002","unstructured":"De Jan Beur SM, Streeten EA, Civelek AC et al (2002) Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359(9308):761\u2013763. https:\/\/doi.org\/10.1016\/S0140-6736(02)07846-7","journal-title":"Lancet"},{"issue":"10","key":"843_CR15","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","volume":"294","author":"SM Jan De Beur","year":"2005","unstructured":"Jan De Beur SM (2005) Tumor-induced osteomalacia. J Am Med Assoc 294(10):1260\u20131267. https:\/\/doi.org\/10.1001\/jama.294.10.1260","journal-title":"J Am Med Assoc"},{"key":"843_CR16","doi-asserted-by":"publisher","unstructured":"Ruppe MD, de Beur SMJ (2013) Disorders of phosphate homeostasis. In: Prim metab bone dis disord miner metab eighth ed. pp 601\u2013612. https:\/\/doi.org\/10.1002\/9781118453926.ch74","DOI":"10.1002\/9781118453926.ch74"},{"issue":"1","key":"843_CR17","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1097\/MPH.0000000000000686","volume":"39","author":"SS Crossen","year":"2017","unstructured":"Crossen SS, Zambrano E, Newman B et al (2017) Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J Pediatr Hematol Oncol 39(1):e21\u2013e24. https:\/\/doi.org\/10.1097\/MPH.0000000000000686","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"843_CR18","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3171\/2015.9.PEDS14617","volume":"17","author":"MB Ellis","year":"2016","unstructured":"Ellis MB, Gridley D, Lal S, Nair GR, Feiz-Erfan I (2016) Phosphaturic mesenchymal tumor of the brain without tumor-induced osteomalacia in an 8-year-old girl: case report. J Neurosurg Pediatr 17(5):573\u2013577. https:\/\/doi.org\/10.3171\/2015.9.PEDS14617","journal-title":"J Neurosurg Pediatr"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00843-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00843-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T23:12:31Z","timestamp":1626045151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00843-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00843-2","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"11 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BA: Consulting and speakers fees Amgen, UCB, Kyowa-Kirin International. Institutional research contracts UCB and Novartis. CDS: None. SM: Served as speaker for Abiogen, Amgen, Bruno Farmaceutici, Diasorin, Eli Lilly, Shire, Sandoz, Takeda. He also served on advisory boards of Abiogen, Kyowa Kirin, Pfizer, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not required under Danish law. Data were maintained by Statistics Denmark (study reference 707,907) and only accessed by the researchers using VPN access to Statistics Denmark servers, with only aggregated statistical tables being allowed to be moved out from the server. The study was approved by the institutional data privacy board for the University of Southern Denmark (10.936) as authorized by the Data Protection Agency and conducted through the Open Patient Data Explorative Network (ref OP 1085).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}